Name | 4-androsten-11B-ol-3,17-dione |
Synonyms | u 2826 4-androsten-11B-ol-3,17-dione 11-BETA-HYDROXYANDROSTENEDIONE 4-ANDROSTEN-11BETA-OL-3,17-DIONE 4-Androstene-11beta-ol-3,17-dione 11-Hydroxyandrost-4-ene-3,17-dione 11beta-Hydroxy-4-androsten-3,17-dione 11BETA-HYDROXY-4-ANDROSTENE-3,17-DIONE Androst-4-ene-3,17-dione, 11beta-hydroxy- Androst-4-ene-3,17-dione, 11-hydroxy-, (11beta)- |
CAS | 382-44-5 |
InChI | InChI=1/C19H26O3/c1-18-8-7-12(20)9-11(18)3-4-13-14-5-6-16(22)19(14,2)10-15(21)17(13)18/h9,13-15,17,21H,3-8,10H2,1-2H3/t13-,14-,15-,17+,18-,19-/m0/s1 |
Molecular Formula | C19H26O3 |
Molar Mass | 302.41 |
Density | 1.19g/cm3 |
Melting Point | 197-199℃ |
Boling Point | 475.3°C at 760 mmHg |
Flash Point | 255.4°C |
Vapor Presure | 4.95E-11mmHg at 25°C |
Storage Condition | -20℃ |
Refractive Index | 1.569 |
MDL | MFCD00051131 |
In vitro study | In order to establish that this conversion is catalysed by the lyase activity of CYP17A1, 21-deoxycortisol (21dF) and 21-deoxycortisone (21dE) is assayed within the LNCaP cell line. Upon the transfection of CYP17A1, 11-Beta-hydroxyandrostenedione (11OHA4)-pathway metabolites increase, 21dF and 21dE are in fact metabolised to 11-Beta-hydroxyandrostenedione and 11-ketoprogesterone (11KP4) by CYP17A1, respectively. |
In vivo study | The plasma concentration of 11-Beta-hydroxyandrostenedione (11beta-hydroxy-4-androstene-3,17-dione) is very high in 21-hydroxylase deficiency, Cushing's syndrome, and hyperandrogenism of adrenal origin, and very low in congenital 11-hydroxylase deficiency and adrenal insufficiency. Thus, when plasma 4-androstenedione is elevated, it is useful to measure the plasma 11-Beta-hydroxyandrostenedione level in order to determine the adrenal or ovarian origin of the hyperandrogenism. |
WGK Germany | 3 |